Anika reports inducement grants under nasdaq listing rule 5635(c)(4)

Bedford, mass., may 12, 2025 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global leader in the osteoarthritis (“oa”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on may 1, 2025, anika granted non-statutory stock options (“options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the nasdaq global select market (“closing price”) on the grant date, to two newly hired non-executive employees. the grants were made pursuant to the anika therapeutics, inc. 2021 inducement plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with nasdaq listing rule 5635(c)(4), were made as a material inducement to the grantee's acceptance of employment with anika as a component of the grantee's employment compensation.
ANIK Ratings Summary
ANIK Quant Ranking